# **Urokit Plus**<sup>®</sup>

Potassium Citrate BP and Citric Acid Monohydrate BP oral solution

### DESCRIPTION

libitified is a combined preparation of Potassium Citrate & Citric Acid. Potassium Citrate is absorbed and metabolized to potassium bicarbonate, this acting as a systemic alkalizer. The effects are essentially those of chlorides before absorption and those of bicarbonates subsequently. Oxidation is virtually complete so that less than 5% of the potassium citrate is excreted in the urine unchanged.

#### INDICATIONS

lond-list Oral Solution is an effective alkalinizing agent useful in those conditions where long-term maintenance of alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract, especially when the administration of sodium salts is undesirable or contraindicated. In addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of acid urine. It is also effective in correcting the acidosis of certain renal tubular disorders where the administration of potassium citrate may be preferable. This product is highly concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary pH around the clock, usually without the necessity of a 2 A.M. dose. This product alkalinizes the urine without producing a systemic alkalosis in recommended dosage. It is highly palatable, pleasant tasting and tolerable, even when administered for long periods. Potassium Citrate does not neutralize the gastric luice or disturb dioestion.

#### DOSAGE AND ADMINISTRATION

bitths Oral Solution should be taken diluted in water according to directions, followed by additional water, if desired. Palatability is enhanced if chilled before taking. Proper dilution may help prevent gastrointestinal injury associated with the oral ingestion of concentrated potassium salt preparations.

#### To relieve discomfort in UTI

Adults and children over 6 years: 10 mL 3 times daily, diluted with 1 glass of water Children 1-6 years: 5 mL 3 times daily, diluted with 1/2 glass of water

# To prevent kidney stones, acidosis caused by kidney diseases, with unicosuric agent to prevent gout:

Adults: 10-15 mL 4 times daily; or as directed by the physician, diluted with 1 glass of water

Pediatric: 5-10 mL 4 times daily; or as directed by the physician, diluted with 1/2 glass of water.

## CONTRAINDICATIONS

Severe renal impairment with oliguria or azotemia, untreated Addison's disease, adynamia episodica hereditaria, acute dehydration, heat cramps, anuria, severe myocardial damage, and hyperkalemia from any cause. Known hypersensitivity to any ingredient.

## SIDE EFFECTS

bitt Ris Oral Solution is generally well tolerated without any unpleasant side effects when given in recommended doses to patients with normal renal function and urinary output.

# WARNING AND PRECAUTION

Large doses may cause hyperkalemia an alkalosis, especially in the presence of renal disease. Concurrent administration of potassium-containing medication, potassium-sparing diuretics, angiotensin-converting enzyme (ACE) inhibitors, or cardiac glycosides may lead to toxicity. Do not exceed recommended dosage. Discontinue use if adverse reaction occurs.

Should be used with caution by patients with low urinary output unless under the supervision of a physician. As with all liquids containing a high concentration of potassium, patients should be directed to dilute adequately with water to minimize the possibility of gastrointestinal injury associated with the oral ingestion of concentrated potassium salt preparations; and preferable, to take each dose after meals to avoid saline laxative effect.

## PHARMACEUTICAL PRECAUTION

Store in dry place and away from light. Keep out of reach of children.

## PACKAGINO

Until Plus and solution: Bottle containing 200 mL of oral solution. Each 5 mL contains Potassium Citrate BP 1500 mg & Citric Acid Monohydrate BP 250 mg.



Manufactured by

ESKAYEF BANGLADESH LIMITED

GAZIPUR, BANGLADESH

® REGD. TRADEMARK

PM03501 V01